Navigation Links
Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
Date:5/1/2008

SOUTH SAN FRANCISCO, Calif., May 1 /PRNewswire/ -- Proteolix, Inc. today announced that patient dosing has commenced in a Phase 2 clinical trial of carfilzomib (PR-171), a selective blocker of proteasome activity, in relapsed solid tumors. A Phase 1b dose-escalation trial of carfilzomib in patients with advanced solid tumors has recently been completed.

The Phase 2 trial will evaluate the safety and efficacy of single-agent carfilzomib in patients with recurrent or advanced solid tumors. Subjects will be enrolled and stratified according to disease type, including non-small cell lung cancer, small cell lung cancer, ovarian cancer and renal cancer. The open-label, multi-center clinical trial is a two-stage design, with pre-determined criteria for continuation after an initial cohort of patients have been treated. Patients enrolled in the study will receive carfilzomib twice a week for three weeks with a one week rest period.

"We are pleased to advance carfilzomib into Phase 2 in patients with solid tumors, building on the positive safety data and encouraging signals of activity observed in our Phase 1b trial," said Lori Kunkel, M.D., Proteolix' Chief Medical Officer. "In addition to its demonstrated anti-tumor activity against hematologic malignancies, carfilzomib's unique profile points to its potential as a new treatment for solid tumor cancers. Carfilzomib exhibits a highly selective mechanism of action for the proteasome, an important therapeutic target for cancer, and we believe this selectivity may reduce or eliminate toxicities seen with other proteasome inhibitors."

"Targeted agents with novel mechanisms of action can complement current treatment regimens and improve outcomes. Carfilzomib has demonstrated tolerability and anti-tumor activity in early studies and these Phase 2 trials in patients with solid tumors are an exciting step forward in the clinical development of the drug," said Kyri Papadopoulos, M.D., a principal investig
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
3. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
4. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. Prolexys Pharmaceuticals Initiates Phase 1 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)...   BioClinica®, Inc ., a specialty clinical ... it has acquired a leading global patient recruitment ...  The acquisition includes affiliates MediciGlobal , Ltd. ... a lost-to-follow-up patient locate service ( L2FU®) ... BioClinica will offer pharmaceutical companies comprehensive ...
(Date:7/6/2015)... Hologic, Inc. (NASDAQ: HOLX ) announced ... results for the third quarter of fiscal 2015 on ... conjunction with the release, management will host a conference ... Interested participants may listen to the call by ... ) or 719-325-4804 (for international callers) and referencing access ...
(Date:7/6/2015)... FARMINGTON, Conn. , July 6, 2015 ... biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for ... need and commercial potential, today announced that it ... E warrants to purchase 21,917,808 shares of its ... 2,191,781 shares of its common stock.  Certain funds ...
Breaking Medicine Technology:BioClinica Acquires MediciGroup 2BioClinica Acquires MediciGroup 3Hologic to Announce Financial Results for the Third Quarter of Fiscal 2015 on Wednesday, July 29, 2015 2Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5
(Date:7/6/2015)... ... July 06, 2015 , ... ... radiology services and ADVOCATE is leading the transition. ADVOCATE, the only 100% radiology, ... their Top 10 Tips for ICD-10. The ten tips are timely and relevant ...
(Date:7/6/2015)... ... 2015 , ... Cancer Hope Network (CHN) has relaunched their ... to chat with the CHN patient services team and connect with a Support ... often the most traumatic experience of a person’s life,” said CHN Executive Director, ...
(Date:7/6/2015)... ... July 06, 2015 , ... With a ... once again teamed up with Family Emergency Shelter Coalition (FESCO) and announced a ... FESCO was created especially to provide emergency services and support for homeless families, ...
(Date:7/6/2015)... ... July 06, 2015 , ... With a new community program ... Livonia Save Our Youth and announced a new charity campaign to raise funds in ... alcohol and drug abuse. Livonia Save Our Youth is a coalition created especially to ...
(Date:7/6/2015)... ... ... Dr. Lawrence Green is now offering the newly FDA-approved Kybella injectable to ... method to dissolve fat cells and is the first of its kind to be ... commonly known as a double chin. Dr. Green participated in clinical trials for Kybella ...
Breaking Medicine News(10 mins):Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2
... July 13, 2010 The decision regarding treatment following ... (DCIS) has long been an area of discussion and ... rates for DCIS remain low, the risk of local ... surgery include radiation therapy and hormone treatment. While ...
... Science Associates, the company that manages the U.S. ... Engineering Technologies, Inc. (BioSET) of Rockville, Maryland, have ... second-generation technology for designing synthetic peptides that are ... are designed to communicate growth signals to cells ...
... HealthDay Reporter , TUESDAY, July 13 (HealthDay News) -- ... decade ago that the blockbuster diabetes drug caused an increased ... to a report published Tuesday in The New York ... its competitor, Actos, the drug company, then known as SmithKline ...
... ARBOR, Mich.---Dostoyevsky and Tolstoy portrayed Russians as a brooding, ... to focus on dark feelings and memories more than ... finds that even though Russians tend to brood, they ... as a result. "Among Westerners, focusing on one,s ...
... health threats ranging from swine flu to bioterrorism to ... vast potential to protect the public. In a paper ... in Emerging Health Threats Journal , public health ... surveillance, detailing innovations on the horizon that may facilitate ...
... Children and young adults with Tourette syndrome can gain control ... suggests. But a specialist in the condition said the ... works. In the study, reported in the July/August ... , researchers used a video to teach 33 people aged ...
Cached Medicine News:Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 2Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 3Health News:Brookhaven Lab and BioSET Inc. patent improved growth factor technology 2Health News:Avandia Heart Risks Buried by Drug Company: Report 2Health News:Avandia Heart Risks Buried by Drug Company: Report 3Health News:Brooding Russians: Less distressed than Americans 2Health News:Researchers envision better disease surveillance to improve public health 2Health News:Can Self-Hypnosis Help Tourette Patients Control Tics? 2
Intermittent catheter...
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
Disease diagnosis and treatment reference sourced from Griffith's 5-Minute Clinical Consult. Save time diagnosing and treating more than 1,200 diseases and conditions....
... Flexible Band is a flexible partial ... alternative for surgeons who desire posterior ... Tailor® Annuloplasty Ring, which is designed ... rings, but like the option of ...
Medicine Products: